Targeted Literature Review to Describe Safety Outcomes in Immune Thrombocytopenia Patients Treated With Thrombopoietin-Receptor Agonists

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/35906
• EU PAS number:
  EUPAS32139
• Study ID:
  35906
• Official title and acronym:
  Targeted Literature Review to Describe Safety Outcomes in Immune Thrombocytopenia Patients Treated With Thrombopoietin-Receptor Agonists
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Finalised

Research institutions and networks

Institutions

Amgen

United States

Study timelines

Date when funding contract was signed

Actual: 04/09/2019

Study start date

Planned: 26/10/2019

Actual: 26/10/2019

Data analysis start date

Planned: 15/11/2019

Actual: 15/11/2019

Date of final study report

Planned: 15/05/2020

Actual: 19/06/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen

Study protocol

Initial protocol

01.02.06 Public Redacted Protocol Ver 1.0 2019-10-15 English

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable